MENU
KYMR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Kymera Therapeutics (KYMR) Ownership - Who owns Kymera Therapeutics?
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives... Show more
Profile
Industry
N/A
Address
200 Arsenal Yards Boulevard
Phone
+1 857 285-5300
Employees
187
Web
https://www.kymeratx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
2.99B
P/E Ratio
N/A
Total Cash
463.15M
Projected Growth
N/A
Total Debt
86.33M
Revenue
58.89M
Risk (Beta)
1.93
Dividend Yield
N/A
Total Cash/Share
7.11
Total Debt/Equity
N/A
Revenue/Share
0.76 USD as % of share price
Fundamentals
KYMR
Capitalization
2.99B
P/E Ratio
N/A
Risk (Beta)
1.93
Dividend Yield
N/A
Total Cash
463M
Total Cash/Share
7.11
Total Debt
86.3M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.76%
Revenue
58.9M
ROE
N/A
Book Value
786M
P/B Ratio
3.83
Cash Flow
N/A
Earnings
-3.11
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
8.49
Current Revenue Per Employee
106250.00
Dividends Per Share - Security
N/A
EBITDA
-232.67M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-26.97
Shares Held By Institutions
2.88B
Shares Outstanding - Current
65.1M
Total Liabilities
132M
Total Volume MTD
N/A
Value
-1
Gain YTD
15.063
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biotechnology company, which engages in curing untreatable diseases and focuses on discovering and developing novel small molecule therapeutics
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
200 Arsenal Yards Boulevard
Phone
+1 857 285-5300
Employees
187
Web
https://www.kymeratx.com